文献速递临床试验与 GCP流行病学与生物统计

吸入糖皮质激素与长效β2受体激动剂作为维持和缓解治疗与持续性哮喘急性发作及症状控制的相关性:系统评价与荟萃分析

Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01

结果显示,在≥12岁患者中,SMART与哮喘急性发作风险降低相关;在4-11岁患者中证据有限。

要点

  • SMART可降低≥12岁持续性哮喘患者的急性发作风险。
  • SMART对比相同剂量吸入激素+LABA控制治疗,RR为0.68。
  • 4-11岁患儿证据有限,需谨慎解读。

核心结论

  • 在持续性哮喘患者中,与吸入糖皮质激素作为控制治疗(联合或不联合长效β2受体激动剂)和短效β2受体激动剂作为缓解治疗相比,单吸入器维持和缓解治疗与较低的哮喘急性发作风险相关。
  • 4至11岁患者的证据有限。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE、Cochrane对照试验中心注册库和Cochrane系统评价数据库,从建库至2016年8月,并更新至2017年11月28日。
  • 纳入随机临床试验或观察性研究,评估SMART对比吸入糖皮质激素(联合或不联合LABA)作为控制治疗和短效β2受体激动剂作为缓解治疗,对象为≥5岁持续性哮喘患者。

主要发现

  • 在≥12岁患者中,SMART对比更高剂量吸入糖皮质激素和LABA作为控制治疗,急性发作风险降低(RR 0.77 [95% CI 0.60-0.98];RD -2.8% [95% CI -5.2%至-0.3%])。
  • 在≥12岁患者中,SMART对比单用吸入糖皮质激素作为控制治疗,观察到类似结果。
  • 在4-11岁患者(n=341;中位年龄8岁[范围4-11];69例[31%]为女性)中,SMART对比更高剂量吸入糖皮质激素作为控制治疗,急性发作风险降低(RR 0.55 [95% CI 0.32-0.94];RD -12.0% [95% CI -22.5%至-1.5%])。
  • 在4-11岁患者中,SMART对比相同剂量吸入糖皮质激素和LABA作为控制治疗,急性发作风险降低(RR 0.38 [95% CI 0.23-0.63];RD -23.2% [95% CI -33.6%至-12.1%])。

临床怎么用

  • 对于≥12岁持续性哮喘患者,可考虑使用SMART方案以降低急性发作风险。
  • 4-11岁患儿使用SMART的证据有限,临床决策需个体化。

局限性

  • 4至11岁患者的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma. OBJECTIVE: To conduct a systematic review and meta-analysis of the effects of SMART in patients with persistent asthma. DATA SOURCES AND STUDY SELECTION: The databases of MEDLINE via OVID, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched from database inception through August 2016 and updated through November 28, 2017. Two reviewers selected randomized clinical trials or observational studies evaluating SMART vs inhaled corticosteroids with or without a LABA used as the controller therapy and short-acting β-agonists as the relief therapy for patients aged 5 years or older with persistent asthma and reporting on an outcome of interest. DATA EXTRACTION AND SYNTHESIS: Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs), risk differences (RDs), and mean differences with corresponding 95% CIs. Citation screening, data abstraction, risk assessment, and strength of evidence grading were completed by 2 independent reviewers. MAIN OUTCOMES AND MEASURES: Asthma exacerbations. RESULTS: The analyses included 16 randomized clinical trials (N = 22 748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler. Among patients aged 12 years or older (n = 22 524; mean age, 42 years; 14 634 [65%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD, -6.4% [95% CI, -10.2% to -2.6%]) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI, 0.60 to 0.98]; RD, -2.8% [95% CI, -5.2% to -0.3%]). Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy. Among patients aged 4 to 11 years (n = 341; median age, 8 [range, 4-11] years; 69 [31%] were female), SMART was associated with a reduced risk of asthma exacerbations compared with a higher dose of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI, 0.32 to 0.94]; RD, -12.0% [95% CI, -22.5% to -1.5%]) or the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.38 [95% CI, 0.23 to 0.63]; RD, -23.2% [95% CI, -33.6% to -12.1%]). CONCLUSIONS AND RELEVANCE: In this meta-analysis of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations. Evidence for patients aged 4 to 11 years was limited.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29554195. doi:10.1001/jama.2018.2769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。